Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference
January 09 2017 - 8:30AM
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical
company focused on treatments for gastrointestinal (GI) diseases,
today announced that its President and Chief Executive Officer,
Dave Gonyer, and its Chief Business Officer, Matt D’Onofrio, will
be attending the JPMorgan Healthcare Conference being held January
9-12, 2017 in San Francisco, Calif.
Evoke will be conducting meetings with
investors, pharmaceutical executives, and healthcare vendors. The
presentation and discussion materials will highlight the Company’s
novel nasal formulation and delivery of metoclopramide, Gimoti™,
for the treatment of symptoms of gastroparesis, results from its
Phase 3 clinical trial, recent regulatory meetings, financial
condition and the market opportunity for Gimoti. The updated
corporate presentation is available at www.EvokePharma.com.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company
focused primarily on the development of drugs to treat GI disorders
and diseases. The Company is developing Gimoti, a metoclopramide
nasal spray for the relief of symptoms associated with acute and
recurrent gastroparesis in women with diabetes mellitus. Diabetic
gastroparesis is a GI disorder afflicting millions of sufferers
worldwide, in which the stomach takes too long to empty its
contents resulting in serious digestive system symptoms.
Metoclopramide is the only product currently approved in the United
States to treat gastroparesis, and is currently available only in
oral and intravenous forms. Gimoti is a novel formulation of this
drug, designed to provide systemic delivery of metoclopramide
through nasal administration. Visit www.EvokePharma.com for
more information.
Safe Harbor Statement
Evoke cautions you that statements included in
this press release that are not a description of historical facts
are forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as "may," "will,"
"should," or "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negatives of these
terms or other similar expressions. These statements are based on
the company's current beliefs and expectations. These
forward-looking statements include statements regarding: Evoke’s
plans to meet with investors and discuss the highlights of Evoke
and Gimoti, the results from its Phase 3 clinical trial, recent
regulatory meetings, financials and the market opportunity for
Gimoti. The inclusion of forward-looking statements should not be
regarded as a representation by Evoke that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Evoke's business, including, without limitation: the data reported
only includes a portion of the patients in the Phase 3 clinical
trial of Gimoti and that the Phase 3 trial failed to reach its
primary endpoint; risks associated with successfully commencing and
receiving favorable results from the planned pharmacokinetic trial;
later developments with the FDA that may be inconsistent with the
already completed pre-NDA meetings, including that the FDA will not
accept selected data from our Phase 3 clinical trial; the FDA may
change its recommendations regarding evaluation of drugs for the
treatment of gastroparesis; the inherent risks of clinical
development of Gimoti; Evoke is entirely dependent on the success
of Gimoti, and Evoke cannot be certain that it will be able to
submit an NDA for Gimoti or obtain regulatory approval for or
successfully commercialize Gimoti; risks associated with
manufacturing new formulations of Gimoti for use in the PK trial;
Evoke’s dependence on third parties for the manufacture of Gimoti
as well as the conduct of the PK trial; Evoke may require
additional funding to complete the PK trial and submit the NDA, and
will require substantial additional funding to commercialize
Gimoti, and may be unable to raise capital when needed, including
to fund ongoing operations; Evoke may not be able to successfully
commercialize Gimoti, if approved, as a result of risks associated
with market acceptance, coverage and reimbursement and competing
products; and other risks detailed in Evoke's prior press releases
and in the periodic reports it files with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof, and Evoke undertakes no obligation to revise or update
this press release to reflect events or circumstances after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement. This caution is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Investor Contact:
The Ruth Group
Tram Bui
Tel: 646-536-7035
tbui@theruthgroup.com
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evoke Pharma (NASDAQ:EVOK)
Historical Stock Chart
From Apr 2023 to Apr 2024